Clinical Trials Logo

Clinical Trial Summary

Absorption, metabolism and excretion of linerixibat have been studied in previous clinical trials. However, no dedicated clinical studies of drug absorption, metabolism, and excretion have been conducted for linerixibat. The purpose of this study is to determine the PK, balance/excretion, and metabolism of radiolabeled 14 Carbon [14C]-linerixibat following a single intravenous (IV) radiolabeled microtracer dose (concomitant with a non-radiolabeled oral dose) and a single oral radiolabeled dose. This is a single group, two period, single sequence, and mass balance study will enroll 6 healthy male subjects. Each subject will be involved in the study for up to 10 weeks which includes screening period, two treatment periods (treatment Periods 1 and 2), separated by about 7 days (at least 13 days between oral doses), and a follow-up visit 1-2 weeks after the last assessment in treatment Period 2.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03992014
Study type Interventional
Source GlaxoSmithKline
Contact
Status Completed
Phase Phase 1
Start date July 8, 2019
Completion date August 26, 2019

See also
  Status Clinical Trial Phase
Completed NCT04510090 - Evaluate the Safety, Tolerability, and PK of EP547 in Healthy Subjects and Subjects With Cholestatic or Uremic Pruritus Phase 1
Completed NCT02917408 - Retrospective Study About Primary Biliary Cholangitis During January 2001 to July 2016 at West China Hospital
Completed NCT00738101 - Compassionate Use of an Intravenous Fish Oil Emulsion in the Treatment of Liver Injury in Infants N/A
Completed NCT00004414 - Sincalide (Cholecystokinin Octapeptide) Versus Placebo in Neonates at High Risk for Developing Parenteral Nutrition Associated Cholestasis N/A
Completed NCT03662282 - Omegaven as Alternative Parenteral Fat Nutrition Phase 3
Recruiting NCT02334293 - Omegaven® as Parenteral Nutrition N/A
Recruiting NCT01252043 - Retrospective Review of CT and MR in Pediatric Patients With Cholestasis N/A
Completed NCT00846963 - Ursodiol for Treating Parenteral Nutrition Associated Cholestasis in Neonates Phase 2/Phase 3
Completed NCT00007033 - Study of Magnesium Sulfate in Children With Reduced Bone Density Secondary to Chronic Cholestatic Liver Disease N/A
Completed NCT01194063 - Use of Omegaven Fish Oil Emulsion for Parenteral Nutrition Associated Liver Disease in Infants and Children Phase 3
Recruiting NCT01998620 - Efficacy and Safety of S-adenosyl-L-methionine in Treatment of Chronic Hepatitis B Patients With Cholestasis Phase 4
Completed NCT00080236 - Safety and Efficacy Study of a Caspase Inhibitor in Patients Undergoing Liver Transplantation Phase 2
Completed NCT00058890 - Gabapentin to Treat Itch in Patients With Liver Disease Phase 3
Active, not recruiting NCT00004315 - Phase II Pilot Study to Compare the Bioavailability of Buffered, Enteric-Coated Ursodiol With Unmodified Ursodiol for Chronic Cholestatic Liver Disease and Cystic Fibrosis-Associated Liver Disease Phase 2
Active, not recruiting NCT02922751 - FibroScan™ in Pediatric Cholestatic Liver Disease (FORCE)
Completed NCT04604652 - Open-Label Study of HTD1801 in Adult Subjects With Primary Biliary Cholangitis Phase 2
Terminated NCT02267707 - Pharmacokinetic and Safety Study of Nab®-Paclitaxel (ABI-007) Plus Gemcitabine in Subjects With Advanced Pancreatic Cancer Who Have Cholestatic Hyperbilirubinemia Phase 1
Completed NCT02357576 - Standard Lipid Therapy vs IVFE Minimization for Prevention of PNALD Phase 3
Completed NCT02721277 - SMOFlipid to Lessen the Severity of Neonatal Cholestasis Phase 1/Phase 2
Terminated NCT02767648 - Inter-regional Cohort of Neonatal and Infant Cholestasis in the Greater Southwest Region N/A